• Ju Fu Tang Biotech released its annual report for the year ended March 31, 2026, highlighting a shift toward health technology.
• Health technology and medical product sales helped lift revenue, partly offsetting weaker demand in civil engineering and renovation work.
• Results swung to a profit, driven mainly by fair-value gains on listed equity securities.
• Portfolio concentration increased, with Asia Strategy Digit Technology Holdings the largest position at HK$27.85 million, or 30.1% of total assets.
• Strategy set to balance a Hong Kong public-sector construction push with continued build-out of health technology and medical devices distribution.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ju Fu Tang Biotech Holdings Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260731-12263711), on July 31, 2026, and is solely responsible for the information contained therein.